Elicio Therapeutics, Inc. (ELTX) Stock

Elicio Therapeutics, Inc. (ELTX) is a Healthcare stock trading at $3.03 (as of 2026-08-21), with a market capitalization of $79.63M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company developing a pipeline of immunotherapies aimed at cancer and other diseases. Its programs include therapeutic and adjuvant vaccine candidates (such as ELI-002 and related agents), additional AMP-peptide vaccines for specific cancer mutations, and a T cell AMP-lifier approach for mKRAS-driven cancers.

Understand Elicio Therapeutics, Inc.: how it makes money

Elicio Therapeutics is a clinical-stage biotech developing immunotherapies for cancer and other diseases, with ELI-002 (an AMP therapeutic vaccine for KRAS-driven cancers) as its lead product candidate and additional AMP-based vaccine programs in development. The provided financial data shows no reported revenue for the latest period.

Because the company is clinical-stage and the provided data shows no revenue, the profit model is structurally driven by trial progress and the durability and breadth of immune responses demonstrated in studies of its AMP vaccine candidates, rather than by current product sales.

Business quality (Weak): Strong set of immunogenicity-related operating KPIs, but limited company financial context in the provided data (no segment breakdown, revenue shown as 0.0, and operating margin is deeply negative).

Bull case

  • Immunogenicity signals are high in the reported AMPLIFY-7P immunogenicity set: Overall Antigen Response Rate is 85.7 percent, and Mutant KRAS-Specific T Cell Response Rate is 99.0 percent.
  • Response breadth is reported across multiple antigen features: Proportion of tested neoantigens with observed T cell responses is 67.5 percent, and Patients Including Response to Patient Tumor Antigens is 87.6 percent.

Bear case

  • No reported revenue in the provided period: Revenue is shown as 0.0B for the period ending 2026-03-31, and the company remains dependent on ongoing clinical development to create future value.
  • Loss-making operating profile in the provided data: Operating margin is -6752.9 for the period ending 2026-03-31.
  • Some immune response analyses are based on relatively small evaluated samples: Number of Evaluable Patients Used for Immune Response Analysis is 12.
Valuation — source: SEC EDGAR (first-party)
Price$3.03
Market Cap$79.63M
Price / Book10.03
Price / Sales122.33
FCF Yield-37.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.30M
Net Margin-1686.5%
Revenue Growth (YoY)7.6%
EPS Growth (YoY)-56.8%
FCF Growth (YoY)6.3%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderKnoll Capital Management, LLC ($6.74M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORobert T. Connelly
Employees32
CountryUS
IPO Date2021-02-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • MAIA Biotechnology, Inc. (MAIA)
  • LifeVantage Corporation (LFVN)
  • Dogwood Therapeutics, Inc. (DWTX)
  • Verrica Pharmaceuticals Inc. (VRCA)
  • Cingulate Inc. (CING)
  • Lunai Bioworks Inc. (LNAI)
  • Annovis Bio, Inc. (ANVS)
  • Telomir Pharmaceuticals, Inc. Common Stock (TELO)
ELTX earnings history · ELTX institutional & insider holders · ELTX KPIs & operating metrics · ELTX financials · ELTX investor presentations & press releases · ELTX SEC filings · ELTX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.